 |
 |
|
|
 |
|
Amnis
Amnis is developing a high-speed
cell analysis technology for clinical and research applications (diagnostics-
cancer, genetic based disease, therapeutics- treatment monitoring).
The company is working with two leading academic institutions and
with a leading pharmaceutical to leverage the technology into drug
discovery applications.
Co-Investors: TVM, Orbi-Med, Hillman, WRF Capital, Sunshine Capital
|
|
All Investments
Active
Investments
Exited
Investments |
| |
|
Ampla Pharmaceuticals
Ampla Pharmaceuticals
- stealth mode biotechnology company.
Co-Investors: Advent International and Crabtree Ventures
|
|
|
 |
|
Blue Heron
Blue Heron is a biotechnology
tools company, which has developed proprietary technology to rapidly
synthesize custom engineered genes. One of the major bottlenecks in
genetic research for pharmaceutical and agricultural companies is
the time and effort required to prepare genes for detailed analysis.
Blue Heron's outsourced service enables researchers to go directly
from planning molecules on the desktop, ordering them over the web,
to testing them in the lab. Blue Heron targets difficult to clone
genes and variants that biotech companies are unable to produce themselves.
Co-Investors: Crabtree Ventures, Invitrogen, Pacific Rim Ventures,
Dr. Lee Hood
|
|
|
 |
|
Calypso Medical Technologies, Inc.
Calypso
Medical Technologies, Inc. is medical device company headquartered
in Seattle, Washington. The company is developing innovative tools
and therapies for the oncology market that address unmet needs in
radiation therapy. Calypso has assembled an experienced management
team, world class biomedical engineers and scientists, and an extensive
scientific advisory board.
Co-Investors: Frazier, Versant, RiverVest, Utah
|
|
|
 |
|
Cardax Pharmaceuticals
Cardax Pharmaceuticals
is a drug discovery and development company targeting large unmet
medical needs where inflammation plays a crucial and often newly defined
pivotal role. The Company’s first product targets cardiovascular
disease. Cardax Pharmaceuticals was spun out from Hawaii Biotech in
May 2006.
Co-Investors: Technology Partners, Arcadia Holdings, Advantage Capital
|
|
|
 |
|
ClearMedical, Inc.
ClearMedical, Inc.
is a Bellevue, Washington based company that significantly reduces
healthcare costs by delivering specialized recycling technology for
disposable medical devices. They provide comprehensive medical device
reprocessing services and meet all quality standards required by regulatory
agencies.
Co-Investors: BDV, Eaglestone
|
|
|
 |
|
Hawaii Biotech, Inc.
Hawaii Biotech,
Inc. is a leader in the development of vaccines to protect from emerging
infectious disease, including avian (pandemic) Influenza, West Nile
encephalitis, and Dengue Fever. Hawaii Biotech's proprietary manufacturing
platform, which exploits recombinant DNA technology to produce commercially
scaleable, ultra-high quality vaccine components, is uniquely suited
to produce commercially-viable vaccines in the quantities and timeframe
needed to address emerging infectious diseases.
Co-investors: Technology Partners, Arcadia Holdings, Advantage Capital
|
|
|
 |
|
MediQuest
MediQuest Therapeutics is a privately held specialty
pharmaceutical company headquartered in Bothell, Washington.
MediQuest Therapeutics, Inc. (MediQuest) is a specialty
pharmaceutical company developing first- and best-in-class topical
therapies in late-stage clinical development to treat patients suffering
from inflammatory and infectious diseases. Using a proprietary drug
delivery technology, MediQuest can deliver a topical, non-systemic
therapy through thickened or diseased skin and nails. The Company's
innovative therapeutic treatments and proprietary drug delivery
have generated a robust product pipeline aimed at treating inflammatory/infectious
diseases and satisfying an unmet medical need.
|
|
|
 |
|
PLx Pharma Inc.
PLx Pharma Inc. is developing
the next generation of non-steroidal anti-inflam-matory drugs (NSAIDs)
for arthritis and cardiovascular markets. PLx has developed novel
formulations of NSAIDs with dramatically reduced gastrointestinal
(GI) toxicities. The Company's lead product, Ibuprofen-PC has completed
Phase III clinical trials, and the GI safety of the formulation is
currently being tested. The formulation platform appears applicable
to increase the therapeutic index of any NSAID.
Co-investors: MediGen Group
|
|
|
 |
|
Targeted Growth
Targeted Growth, Inc.
was founded in 1999 with a goal of developing technologies that would
increase the productivity of existing farmland and create new crops
for use on land otherwise unsuitable for agriculture. Today, Targeted
Growth is a global leader in bioscience, having developed technologies
that both increase seed size and yield in major biofuel crops. The
company has strategic partnerships with leading researchers and agribusinesses
around the world. Targeted Growth is based in Seattle, Wash. with
labs in Seattle, Saskatchewan, Ottawa and New Brunswick.
Co-investors: GrowthWorks, Investment Saskatchewan,
Capricorn Management, AllianceBernstein, WRF Capital
|
|
|
 |
|
Tepha
Tepha is a Cambridge, MA based
medical device and biomaterial manufacturer that is developing resorbable
materials for medical uses. The company manufactures polyhydroxybutyrate
biopolymers synthesized in bacteria that have a number of advantages
over current materials including absorbability and tissue friendliness.
In addition, these polymers are comprised of building blocks that
metabolize into naturally occurring molecules. These biopolymers can
be manufactured into a number of different products from sutures and
hernia meshes to heart valves and ligaments.
Co-Investors: Vertical, Novartis
|
|
|
 |
|
WellPartner
Wellpartner is an innovative provider of comprehensive
pharmacy fulfillment solutions. It delivers straightforward,
transparent and personalized pharmacy fulfillment for individuals
with chronic and recurring medication needs who are beneficiaries
of commercial and Medicaid health plans, pharmacy benefit administrators,
or the health care safety-net nationwide. The Company's extensive
experience with the federal 340B drug discount program, combined with
its expanding pharmacy fulfillment options, has enabled Wellpartner
to become the largest provider of contract pharmacy programs in the
U.S.
Wellpartner
has been recognized as one of the fastest growing private companies
in the U.S. and was recently ranked #119 in Inc. Magazine’s
list of the 500 fastest growing companies in the U.S. for 2006.
Co-Investors: Mediphase, Buerk
Dale Victor, Scorpion, Burrill & Company, Apposite Capital
|
|
|
|
|
|
|
|
|
|
